
According to data from Benzinga Pro, during Q1, Avidity Biosciences's (NASDAQ:RNA) reported sales totaled $1.79 million. Despite a 11.17% increase in earnings, the company posted a loss of $34.23 million. Avidity Biosciences collected $1.85 million in revenue during Q4, but reported earnings showed a $38.54 million loss.